Oct 24 (Reuters) - Tyra Biosciences Inc :
* TYRA BIOSCIENCES REPORTS INTERIM CLINICAL PROOF-OF-CONCEPT DATA FOR TYRA-300, AN INVESTIGATIONAL ORAL FGFR3-SELECTIVE INHIBITOR, IN PHASE 1/2 SURF301 STUDY IN PATIENTS WITH METASTATIC UROTHELIAL CANCER $(MUC)$
* TYRA BIOSCIENCES INC - TYRA-300 GENERALLY WELL-TOLERATED WITH INFREQUENT FGFR2/FGFR1 TOXICITIES
* TYRA BIOSCIENCES INC - 4 SERIOUS ADVERSE EVENTS RELATED TO TYRA-300
* TYRA BIOSCIENCES INC - POSITIVE SAFETY RESULTS ACROSS ALL QD DOSES
Source text for Eikon: Further company coverage:
((Reuters.Brief@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。